Chatuphalatika对痛风高尿酸血症的药理作用,Pharmaceutical Biology

当前位置： X-MOL 学术 › Pharm. Biol. › 论文详情

Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)

Chatuphalatika对痛风高尿酸血症的药理作用
Pharmaceutical Biology ( IF 3.9 ) Pub Date : 2018-01-01 , DOI: 10.1080/13880209.2017.1421235
Vilasinee Hirunpanich Sato ₁ , Bunleu Sungthong ₂ , Prasob-Orn Rinthong ₂ , Narawat Nuamnaichati ₁ , Supachoke Mangmool ₁ , Savita Chewchida ₃ , Hitoshi Sato ₄

Affiliation

摘要背景：Chatuphalatika (CTPT)，是余甘子的泰国草药配方混合物。(大戟科), Terminalia belerica Linn。(Combretaceae)、T. chebula 和 T. arjuna (Roxb.) Wight & Arn 的果实。CTPT被认为具有抗炎和抗高尿酸血症的作用，但没有报道以定量的方式证明这些药理作用。目的：探讨CTPT的抗氧化、抗炎和抗高尿酸血症作用。材料和方法：通过 DPPH、ABTS 和 FRAP 测定法测定 CTPT 提取物的体外抗氧化活性，并通过测定脂多糖 (LPS) 在 RAW264.7 巨噬细胞中诱导的炎症介质产生来测定抗炎作用。使用口服给予 250、500 和 1000 mg/kg CTPT 治疗的氧酸盐诱导的高尿酸血症 ddY 小鼠研究了低尿酸血症作用的机制。结果：通过 ABTS 和 FRAP 测定法测量的 CTPT 的抗氧化活性分别为 1.35 g TEAC/g 提取物和 10.3 mmol/100 g 提取物。抑制 DPPH 自由基的 IC50 为 13.8 µg/mL。CTPT (10 µg/mL) 显着下调 RAW 264.7 细胞中 TNF-α 和 iNOS 的 mRNA 表达。酶动力学的 Lineweaver-Burk 分析表明 CTPT 以非竞争性方式抑制黄嘌呤氧化酶 (XOD) 活性，Ki 为 576.9 µg/mL。口服 CTPT (1000 mg/kg) 通过抑制肝脏 XOD 活性显着抑制尿酸生成，并将高尿酸血症小鼠的血浆尿酸水平降低约 40% (p < 0.05)。

"点击查看英文标题和摘要"

Pharmacological effects of Chatuphalatika in hyperuricemia of gout

Abstract Context: Chatuphalatika (CTPT), is a Thai herbal formulation mixture of Phyllanthus emblica Linn. (Euphorbiaceae), Terminalia belerica Linn. (Combretaceae), T. chebula and the fruit of T. arjuna (Roxb.) Wight & Arn. CTPT is considered to exert anti-inflammatory and antihyperuricemic effects, but there have been no reports to demonstrate these pharmacological effects in a quantitative manner. Objectives: To investigate the antioxidative, anti-inflammatory and antihyperuricemic effects of CTPT. Materials and methods: Antioxidant activities of CTPT extracts were measured in vitro by DPPH, ABTS and FRAP assays, and anti-inflammatory effect by measuring inflammatory mediator production induced by lipopolysaccharide (LPS) in RAW264.7 macrophages. The mechanism of the hypouricemic effect was investigated using oxonate-induced hyperuricemic ddY mice treated with oral administrations of CTPT at 250, 500 and 1000 mg/kg. Results: Antioxidant activities of CTPT measured by ABTS and FRAP assays were 1.35 g TEAC/g extract and 10.3 mmol/100 g extract, respectively. IC50 for the inhibition of DPPH radical was 13.8 µg/mL. CTPT (10 µg/mL) significantly downregulated the mRNA expression of TNF-α and iNOS in RAW 264.7 cells. Lineweaver–Burk analysis of the enzyme kinetics showed that CTPT inhibited xanthine oxidase (XOD) activity in a noncompetitive manner with the Ki of 576.9 µg/mL. Oral administration of CTPT (1000 mg/kg) significantly suppressed uric acid production by inhibiting hepatic XOD activity, and decreased plasma uric acid levels in hyperuricemic mice by approximately 40% (p < 0.05). Conclusions: This study demonstrated for the first time the antioxidative, anti-inflammatory and antihyperuricemic effects of CTPT in vivo and in vitro, suggesting a possibility of using CTPT for the treatment of hyperuricemia in gout.

更新日期：2018-01-01

点击分享查看原文

点击收藏

公开下载

阅读更多本刊新发论文本刊介绍/投稿指南